Radiofrequency (RF) Ablation for Atrial Fibrillation (AF) in Patients With Heart Failure With Preserved Ejection Fraction

Inclusion Criteria: * Age ≥ 50 years at date of consent. * LVEF \>50% as determined on imaging study measured in the last 6 calendar months prior to or on consent date. * Hospitalized for HF within the past 12 calendar months prior to consent date. * Stabilized patients defined as being off all IV therapies for at least 24 hours prior to consent date. * Paroxysmal AF diagnosed within the past 6 calendar months or early persistent AF, defined as an AF episode lasting greater than 7 days but less than 6 calendar months prior to consent date. * Indicated for oral anticoagulation according to current guidelines (CHA2DS2-VASc ≥ 2 in men or ≥ 3 in women at the time of consent)\* * Patient with CIED in situ at time of consent or scheduled to undergo ICM implant for AF management within 2 calendar months of randomization. Exclusion Criteria: * Previous catheter or surgical ablation of AF any time in the past. * Long-standing persistent AF (\>1-year prior to consent date) or permanent AF. * Chronic pulmonary disease requiring home oxygen or oral/IV steroid therapy in the past 12 calendar months prior to consent date. * Active infection at time of consent but may be re-considered for enrollment later after effective treatment. * Left atrial size \>50 mm as measured by echo in the past 6 calendar months prior to consent date. * Untreated obstructive sleep apnea any time in past. * Myocardial infarction in past 3 calendar months prior to consent date. * Coronary artery bypass graft (CABG) surgery in past 3 calendar months prior to consent date. * Stroke in past 3 calendar months prior to consent date. * Intra-cardiac thrombus precluding ability to undergo AF ablation at time of consent but may be re-considered for enrollment later after effective treatment. * Infiltrative cardiomyopathy (sarcoid, amyloid) any time in past. * Active myocarditis at time of consent but may be re-considered for enrollment later after effective treatment. * Hypertrophic cardiomyopathy at any time in past. * Known pericardial constriction. * Uncontrolled hypertension (SBP \> 160 mmHg) at time of consent but may be re- considered for enrollment later after effective treatment. * Untreated hypothyroidism or hyperthyroidism but may be re-considered for enrollment later after effective treatment. * Pregnancy or nursing. * Valvular AF or presence of a prosthetic valve. * Undergoing dialysis or have advanced renal dysfunction (eGFR \<30 ml/min/m2) defined as 3 times the upper limits of AST or ALT during the past 6 calendar months. * Contraindication to anticoagulation. * Metabolic derangements (e.g. renal/hepatic failure, electrolyte disturbance, etc.), prohibiting study (EP) study and ablation. * Cognitive impairment. * Life expectancy \< 1 year following consent date. * Unwilling to comply with all study protocol-required testing. * Unwilling or unable to give informed consent.